Canadian drug discovery company Phytobiotech has entered into an agreement to supply Achillion Pharmaceuticals with purified, plant derived small molecules (phytochemicals) from its PurePhytoLib library. The collaboration marks a deeper investment in the discovery of new drugs that address novel infectious disease targets.
"Compound libraries of natural products offer a rich source of chemical diversity, but often the pharmaceutically interesting compounds are difficult to separate from the mixture," said Milind Deshpande, vice president of Drug Discovery at Achillion.
"Phytobiotech has addressed this dilemma by creating unique small molecules assembled from plant cell cultures that are compatible with high-throughput drug discovery processes. From this collaboration we are able to exploit our infectious disease targets to screen for potential clinical candidates from an increasingly diverse chemical library."
Although terms of the agreement were not disclosed both companies will set out to develop drug candidates for infectious diseases.
Kevin Eastwood, senior director of business development at Achillion commented:"This collaboration capitalises on the resources of both organisations to identify novel chemotypes derived from plants for the treatment of serious infectious diseases, leveraging both Phytobiotech's novel chemical diversity and Achillion's drug discovery and clinical development expertise."